Who makes QL2109 or Daratumumab?

QL2109 or Daratumumab is developed by Qilu Pharmaceutical Co., Ltd..

What development phase is QL2109 or Daratumumab in?

QL2109 or Daratumumab is in Phase 2.

Last reviewed 2026-04-19 · How we verify

QL2109 or Daratumumab

Qilu Pharmaceutical Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	QL2109 or Daratumumab
Sponsor	Qilu Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma (PHASE2)
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

QL2109 or Daratumumab CI brief — competitive landscape report
QL2109 or Daratumumab updates RSS · CI watch RSS
Qilu Pharmaceutical Co., Ltd. portfolio CI